Kamada
Pharmaceuticals, 75 2nd Ave, Needham Heights, Massachusetts, 02494, United States, 201-500 Employees
Phone Number: 97*********
Who is KAMADA
Kamada is focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and kn...
Read More
-
Headquarters: 75 2nd Ave, Needham Heights, Massachusetts, 02494, United States
-
Date Founded: 1990
-
Employees: 201-500
-
Revenue: $250 Million to $500 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 5989
KAMADA Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding KAMADA
Answer: KAMADA's headquarters are located at 75 2nd Ave, Needham Heights, Massachusetts, 02494, United States
Answer: KAMADA's phone number is 97*********
Answer: KAMADA's official website is https://kamada.com
Answer: KAMADA's revenue is $250 Million to $500 Million
Answer: KAMADA's SIC: 5989
Answer: KAMADA has 201-500 employees
Answer: KAMADA is in Pharmaceuticals
Answer: KAMADA contact info: Phone number: 97********* Website: https://kamada.com
Answer: Kamada is focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Companys flagship product is GLASSIA, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA in the U.S. through a strategic partnership with Baxalta (now part of Shire plc) and in other counties through local distributors. In addition to GLASSIA, Kamada has a product line of six other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada's rabies immune globulin (Human) product received FDA approval for Post-Exposure Prophylaxis against rabies infection and is marketed in the U.S. through a partnership with Kedrion Biopharma. Kamada has late-stage products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency and, in addition, its intravenous AAT is in development for other indications, such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 complementary products in Israel that are manufactured by third parties.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month